Drug | Condition | Co-treatment | Primary outcome measure | N | Phase | Status | NCT number |
---|---|---|---|---|---|---|---|
DNMT inhibitor | Â | Â | Â | Â | Â | Â | Â |
Azacitidine | Advanced BC | Entinostata | Objective response rate | 60 | II | R | 01349959 |
 | Advanced/metastatic BC | Nab-paclitaxel |  | 45 | I/II | R | 00748553 |
Decitabine | Advanced/metastatic TNBC | Panobinostatb (±tamoxifen) | The maximum tolerated dose of decitabine and panobinostat | 60 | I/II | R | 01194908 |
FdCyd | Solid tumors, including BC | Tetrahydrouridine | To determine the safety of FdCyd | 20 | I | R | 01479348 |
FdCyd | Solid tumors, including BC | Tetrahydrouridine | To determine PFS and/or response rate of FdCyd plus tetrahydrouridine | 185 | I | R | 00978250 |
EGCG | Newly diagnosed BC | - | To determine whether EGCG can affect proliferation rate and induce apoptosis | 20 | II | R | 00949923 |
 | Newly diagnosed BC | - | To evaluate the effects of EGCG on various biomarkers | 32 | II | A | 00676793 |
 | Stage I-III BC | - | To determine the safety and maximum tolerated dose of EGCG | 40 | I | A | 00516243 |
HDAC inhibitor | Â | Â | Â | Â | Â | Â | Â |
Vorinostat | BC | Lapatinib | Clinical benefit rate | 47 | I/II | R | 01118975 |
 | Recurrent/metastatic BC | - | To evaluate the safety of vorinostat | 49 | I/II | A | 00416130 |
 | Advanced BC | Capecitabine | The maximum tolerated dose, safety, and efficacy of vorinostat plus capecitabine | 47 | II | U | 00719875 |
 | Local recurrent/metastatic BC | Paclitaxel/bevacizumab | The maximum tolerated dose, and objective response rate of vorinostat in combination with paclitaxel/bevacizumab | 58 | I/II | U | 00368875 |
 | Metastatic BC | Ixabepilone | Dose limiting toxicity | 56 | I | A | 01084057 |
 | Hormone-refractory BC | Aromatase inhibitor | Clinical benefit rate | 14 | II | R | 01720602 |
 | Locally advanced BC | Paclitaxel/trastuzumab | To determine the recommended phase II dose | 54 | I/II | U | 00574587 |
 | Hormone-refractory BC | Aromatase inhibitor | Clinical benefit rate | 20 | II | R | 01153672 |
 | Newly diagnosed BC | Nab-paclitaxel/carboplatin | Pathologic complete response rate | 74 | II | A | 00616967 |
 | HIV + with solid tumor, including BC | Paclitaxel/carboplatin | Maximum tolerated dose | 66 | I | R | 01249443 |
 | Brain metastases, including from BC | Paclitaxel/carboplatin plus radiotherapy | Maximum tolerated dose | 24 | I | A | 00838929 |
Entinostat | Locally recurrent/metastatic ER + BC, or NSCLC | ±Exemestane | Pharmacokinetics of entinostat in fasted and fed subjects | 28 | I | R | 01594398 |
 | Newly diagnosed TNBC | Anastrozole | Safety, tolerability and recommended phase II dose (phase I cohort); change in proliferation, ER/PR expression (phase II cohort) | 41 | I/II | R | 01234532 |
 | HER2-positive metastatic BC | Lapatinib | Recommended phase II dose (phase I cohort); objective response rate (phase II cohort) | 70 | I/II | R | 01434303 |
 | Advanced BC | Azacitidinea | Objective response rate | 60 | II | R | 01349959 |
Panobinostat | Metastatic TNBC | Letrozole | Maximum tolerated dose, adverse events (phase I cohort); response rate (phase II cohort) | 48 | I/II | R | 01105312 |
 | Advanced/metastatic TNBC | Decitabineb (±tamoxifen) | The maximum tolerated dose of decitabine and panobinostat | 60 | I/II | R | 01194908 |
 | HER2-negative locally recurrent/metastatic BC | - | Objective response rate | 118 | II | A | 00777049 |
VPA | Newly diagnosed locally advanced/metastatic BC | FEC | Pathologic response rate | 55 | II | R | 01010854 |
 | Newly diagnosed BC | - | To determine whether VPA levels correlate with leukocyte and tumor histone acetylation | 33 | NA | R | 01007695 |
Depsipeptide | Solid or hematologic malignancy, including BC | - | Safety, tolerability, maximum tolerated dose and pharmacokinetics | 132 | I | R | 01638533 |